logo-loader
viewEmerald Health Therapeutics Inc

Canadian cannabis company Emerald Health Therapeutics files 17 US patent applications to protect product line

The patent applications advance the company's efforts to develop distinctive cannabis products for medical use as well as recreational purposes

patents
Cannabis is not legal at the federal level, but the US is considered an important “first to file” jurisdiction for intellectual property pertaining to cannabis

The cannabis company Emerald Health Therapeutics Inc (CVE:EMH, OTCQX:EMHTF) has filed 17 US patent applications to protect its array of Defined Dose cannabis dosage forms and formulations.

The new patent applications contribute to Emerald’s intellectual property portfolio and advance its efforts to develop distinctive cannabis products for medical use as well as recreational purposes.

Although cannabis is not legal at the federal level in the US, it is considered an important “first to file” jurisdiction for intellectual property pertaining to cannabis and cannabinoids. The Patent Cooperation Treaty permits Emerald to file Canadian and international versions of these US patent applications in 152 countries over the coming year.

The 17 patent applications relate to inhaled dosage forms for smoking as well as vaping and also cover capsule and edible cannabis.

READ: Emerald Health Therapeutics partners with cannabis researcher VivaCell to boost patent portfolio

Emerald Health is a licensed producer authorized by Health Canada to grow, sell and produce cannabis across the country.

A number of the Defined Dose cannabis products are already eligible for launch in Canada as the country is set to legalize recreational marijuana, starting tomorrow. But other products are set to be eligible following regulatory changes next year.

“We expect significant potential cannabis market growth by offering adult users and medical consumers consistent product characteristics, dosing regimens, and alternative methods of consumption, with safety-enhanced through GMP-compliant production and enhance product utility achieved through knowledge of science,” said CEO Emerald Chris Wagner. “Emerald’s filing of these patent applications is an important step.”

Emerald also recently strengthened its intellectual property portfolio via a partnership with the cannabis-focused research facility VivaCell Biotechnologies. The institute will work with Emerald Health to evaluate formulas and determine consistent dosages as the company continues to develop medical and recreational cannabis products.

Emerald Health closed up 4.7% to hit $3.92 on Monday.

Contact Ellen Kelleher at [email protected]

Quick facts: Emerald Health Therapeutics Inc

Price: 0.58 CAD

TSX-V:EMH
Market: TSX-V
Market Cap: $86.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Animoca Brands launches Addams Family mobile game and leads investment round...

Animoca Brands Corporation Limited (ASX:AB1) chairman and co-founder Yat Siu updates Proactive on the launch of the official mobile game for Metro Goldwyn Mayer Studios (MGM) film of “The Addams Family”. The chairman also updates the market on entering into a subscription agreement with Sky...

6 hours, 34 minutes ago

2 min read